TWST Stock Analysis: Twist Bioscience | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 9.495m USD | 12M Return: 441.3% | US90184D1000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 200M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells DNA-based products, including synthetic genes and gene fragments, oligo pools, immunoglobulin G (IgG) proteins, next-generation sequencing (NGS) tools, and methylation detection kits. Its products serve a diverse customer base spanning biotech, pharmaceutical, industrial chemical, and agricultural companies, as well as academic and government research laboratories.
The companys offerings support applications across therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research. Twist also supplies synthetic viral reference sequences and research panels, including products targeting SARS-CoV-2, monkeypox, and other respiratory pathogens, and provides precision DNA libraries and antibody optimization tools for drug discovery and development.
Twist maintains a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California. It trades on the NASDAQ under the ticker TWST and went public on October 31, 2018.
- Synbio revenue accelerates as gene synthesis demand rises
- NGS tools margins expand on library prep kit adoption
- Biopharma antibody partnerships drive recurring revenue growth
| Net Income: -136.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.17 > 1.0 |
| NWC/Revenue: 46.56% < 20% (prev 69.76%; Δ -23.20% < -1%) |
| CFO/TA -0.08 > 3% & CFO -53.1m > Net Income -136.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago 2.03% < -2% |
| Gross Margin: 51.97% > 18% (prev 49.24%; Δ 2.72% > 0.5%) |
| Asset Turnover: 65.62% > 50% (prev 56.29%; Δ 9.33% > 0%) |
| Interest Coverage Ratio: -49.81 > 6 (EBIT TTM -133.2m / Interest Expense TTM 2.67m) |
| A: 0.30 (Total Current Assets 321.3m - Total Current Liabilities 120.3m) / Total Assets 672.4m |
| B: -2.13 (Retained Earnings -1.43b / Total Assets 672.4m) |
| C: -0.20 (EBIT TTM -133.2m / Avg Total Assets 658.0m) |
| D: 1.97 (Book Value of Equity 445.7m / Total Liabilities 226.7m) |
| Altman-Z'' = -4.26 = D |
| DSRI: 1.11 (Receivables 65.8m/49.9m, Revenue 431.8m/362.3m) |
| GMI: 0.95 (GM 49.24% / 51.97%) |
| AQI: 1.04 (AQ_t 0.25 / AQ_t-1 0.24) |
| SGI: 1.19 (Revenue 431.8m / 362.3m) |
| TATA: -0.12 (NI -136.7m - CFO -53.1m) / TA 672.4m) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of August 27, 2026, the stock is trading at USD 150.06 with a total of 1,209,309 shares traded. Over the past week, the price has changed by +5.39%, over one month by +73.40%, over three months by +131.32% and over the past year by +441.34%.
Current recommended Stop Loss: 137.90 (which is 8.1% or 1.3 ATR below the current price).
Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.
- StrongBuy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 105.3 | -29.8% |
P/S = 21.9898
P/B = 19.8073
Revenue TTM = 431.8m USD
EBIT TTM = -133.2m USD
EBITDA TTM = -107.8m USD
Long Term Debt = 85.0m USD (estimated: total debt 93.6m - short term 8.63m)
Short Term Debt = 8.63m USD (from shortTermDebt, last quarter)
Debt = 93.6m USD (from shortLongTermDebtTotal, last quarter) (leases 93.6m already included)
Net Debt = -73.2m USD (calculated: Debt 93.6m - CCE 166.8m)
Enterprise Value = 9.42b USD (9.50b + Debt 93.6m - CCE 166.8m)
Interest Coverage Ratio = -49.81 (Ebit TTM -133.2m / Interest Expense TTM 2.67m)
EV/FCF = -101.2x (Enterprise Value 9.42b / FCF TTM -93.1m)
FCF Yield = -0.99% (FCF TTM -93.1m / Enterprise Value 9.42b)
FCF Margin = -21.57% (FCF TTM -93.1m / Revenue TTM 431.8m)
Net Margin = -31.66% (Net Income TTM -136.7m / Revenue TTM 431.8m)
Gross Margin = 51.97% ((Revenue TTM 431.8m - Cost of Revenue TTM 207.4m) / Revenue TTM)
Gross Margin QoQ = 52.76% (prev 51.59%)
Tobins Q-Ratio = 14.01 (Enterprise Value 9.42b / Total Assets 672.4m)
Interest Expense / Debt = 2.86% (Interest Expense 2.67m / Debt 93.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -105.2m (EBIT -133.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.67 (Total Current Assets 321.3m / Total Current Liabilities 120.3m)
Debt / Equity = 0.21 (Debt 93.6m / totalStockholderEquity, last quarter 445.7m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -73.2m / EBITDA -107.8m)
Debt / FCF = 0.79 (negative FCF - burning cash) (Net Debt -73.2m / FCF TTM -93.1m)
Total Stockholder Equity = 457.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.78% (Net Income -136.7m / Total Assets 672.4m)
RoE = -29.89% (Net Income TTM -136.7m / Total Stockholder Equity 457.5m)
RoCE = -24.55% (EBIT -133.2m / Capital Employed (Equity 457.5m + L.T.Debt 85.0m))
RoIC = -19.51% (negative operating profit) (NOPAT -105.2m / Invested Capital 539.2m)
WACC = 14.50% (E(9.50b)/V(9.59b) * Re(14.62%) + D(93.6m)/V(9.59b) * Rd(2.86%) * (1-Tc(0.21)))
Discount Rate = 14.62% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 96.94 | Cagr: 3.48%
[DCF] Fair Price = unknown (Cash Flow -93.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.76 | # QB: 0
Revenue Correlation: 99.63 | Revenue CAGR: 22.23% | SUE: 3.24 | # QB: 4
EPS current Quarter (2026-12-31): EPS=-0.05 | Chg30d=+47.37% | Revisions=+0% | Analysts=2
EPS current Year (2026-09-30): EPS=-0.60 | Chg30d=+22.08% | Revisions=+40% | GrowthEPS=+71.6% | GrowthRev=+21.2%
EPS next Year (2027-09-30): EPS=-0.63 | Chg30d=+17.03% | Revisions=+0% | GrowthEPS=-5.5% | GrowthRev=+18.2%
[Analyst] Revisions Ratio: +22% (up=4, down=2)